GLP1R and type 2 diabetes mellitus: To uncover plausible molecular mechanisms responsible for the observed impact of GLP-1R agonist treatment on urinary peptides in T2DM patients, the proteases potentially responsible for the cleavage of the 70 statistically significant peptides were investigated using Proteasix.